Cached score snapshot

US.GILD · Gilead Sciences

110分制 51.6/110；5D動能v2 1/50；排序分 52.6/160

Back to ranking Open volume snapshot

Ranking score 52.6/160

Main score 51.6/110

5D momentum v2 1/50

Rank #364

Setup grade F 23.8

Score breakdown

避免

Medium twelvedata

Score and price trend

F 23.8 Low sample confidence

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

**Historical projection**
Model	Median	P25/P75	歷史相似情境上漲比例	Down5	Actual / compare
Rolling DOE best · score 2.297 · anchors 120	+0.99%	-1.07% / +3.23%	60%	1.9%	Actual +2.64% · vs median +1.65% · inside 25-75 band
30D observation	+6.73%	+1.73% / +12.02%	80%	6.9%	Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160	+1.21%	-1.06% / +3.26%	63.1%	1.3%	Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup；圖中投影中位線為統計中位數的線性插值展示，並非價格路徑預測或買賣建議。

2026-04-29 → 2026-09-04 · 293 archived points · 3 Improving turn signal · 6 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 52.6

Display grade 避免

Model version cursor_18_27_news_v2_160

Main score 51.6/110 (避免)

5D momentum v2 1/50 (弱)

Score with momentum v2 52.6/160 (低排序)

Risk level Medium

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60

ma20 131.0985

ma50 129.653

close 129.31

prevClose 130.86

avgVolume20 7392030

volumeRatio 0.75

changePercent -1.18

Metrics snapshot

close 129.31

volume 5529600

changePercent -1.18

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 51.6/110

Main rating 避免

5D momentum v2 1/50

Score with momentum v2 52.6/160

Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 4.6/5 · 優秀

Dimension score 4.6/5

Dimension grade 優秀

Sub-items

pbPoints 0.2

pePoints 0.5

epsPoints 0.6

roePoints 0.75

debtPoints 0.4

marginPoints 0.75

turnoverUsdM 715.0326

volumePoints 0.5

revenuePoints 0

dividendPoints 0.4

marketCapPoints 0.5

資金流 — 10.8/20 · 較差

Dimension score 10.8/20

Dimension grade 較差

Sub-items

cmfPoints 1.6

mfiPoints 2.4

obvPoints 4

vwapPoints 0.8

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL

symbol US.GILD

message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.

optional true

holderCount n/a

holderPoints 2

top10ShareRatio n/a

concentrationPenalty 0

institutionPoints 2

市場環境 — 6.2/15 · 較差

Dimension score 6.2/15

Dimension grade 較差

Sub-items

vix

score 1.8

details

source twelvedata+fred

vixClose 18.7

trend

score 0.8

details

qqq

ma20 711.713

ma50 718.2872

name QQQ

close 684.23

points 0.4

spy

ma20 746.153

ma50 745.068

name SPY

close 738.93

points 0.4

source twelvedata+fred

atrPct 3.0629

atrPoints 2

cciPoints 1.6

vixPoints 1.8

marketTrendPoints 0.8

催化劑 — 2/20 · 較差

Dimension score 2/20

Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model

articleCount 8

catalystCount 0

catalystPoints 2

風險管理 — 6.5/10 · 一般

Dimension score 6.5/10

Dimension grade 一般

Sub-items

position

score 1.3

details

atrPct 3.0629

turnoverUsdM 715.0326

liquidityPoints 0.6

volatilityPoints 0.7

rrPoints 1.4

stopLevels

symbol US.GILD

rr_range 1:1.0-1:2.5

risk_profile 中等

stop_loss_price 121.3886

strength_details

ma_score 2

atr_score 1

rsi_score 1

macd_score 1.5

volume_score 1

market_adjustment 1

risk_reward_ratio 1

stop_loss_percent 6.1

take_profit_price 135.7755

target_multiplier 1.6

technical_strength 1.33

take_profit_percent 5

positionPoints 1.3

stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used

sector Health Care

concentratedSectorPenalty 0

riskRewardRatio 1.2

stopLossPercent 6.1259

diversificationPoints 2

技術信號 — 17.5/30 · 較差

Dimension score 17.5/30

Dimension grade 較差

Sub-items

bbPoints 2.4

adxPoints 3

sarPoints 1.2

vcpPoints 1.8

macdPoints 2.4

vcpPayload

vcp_pass false

vcp_score 1.8

vcp_reason 波幅收縮(14.9%→10.1%)；跌縮量(近10日3日)；Ready=N；Confirm=N

vcp_metrics

up_days 5

vol_ref 7856793.3333

down_days 4

vcp_ready false

above_ma50 false

avg_vol_10 5915300

avg_vol_20 7478065

avg_vol_30 7856793.3333

range_pct_10 0.1005

range_pct_20 0.131

range_pct_30 0.1486

up_expand_ok false

lookback_used 59

near_20d_high false

contraction_ok true

down_shrink_ok true

up_expand_days 1

breakout_20d_ok false

vol_ratio_10_30 0.7529

dist_to_20d_high 0.0804

down_shrink_days 3

breakout_level_20d 140.61

vcp_breakout_confirm false

contraction_ratio_10_30 0.6764

vcp_name_en Volatility Contraction Pattern

vcp_name_zh 波動收縮形態

vol_contraction true

kdjAdxPoints 0.5

rsiKdjPoints 2.4

volumeWeight 2

maCrossPoints 2.4

shortRsiPoints 0

shortMacdPoints 0.4

volConfirmPoints 0.6

volumePointsTechnical 0.4

情緒分析 — 4/10 · 較差

Dimension score 4/10

Dimension grade 較差

Sub-items

sentiment

score 4

details

source finnhub_news_keyword_model

articleCount 8

negativeHits 0

positiveHits 2

sentimentScoreRaw 0.6

sentimentData

raw {"id":141012190,"url":"https://finnhub.io/api/news?id=51fa8d6c7ae0b7ae5efeba304c16da4ea1ae8d7c25870a47a7c47e0f7c9348a5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.","category":"company","datetime":1784930402,"headline":"Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"}, {"id":141004172,"url":"https://finnhub.io/api/news?id=320990a0a77a181b5302b8633572bf2b889ef0eb3204a5649fbc5f850ba940bc","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.","category":"company","datetime":1784891430,"headline":"Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"}, {"id":140979262,"url":"https://finnhub.io/api/news?id=9203bb8e2107fe13e333d0412f970c8c33cf9b4acec8cf74ecec2b8c1c045ac4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...","category":"company","datetime":1784694517,"headline":"Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026"}, {"id":140939218,"url":"https://finnhub.io/api/news?id=0e03b539cb341075b72f4a43979aac043c7a90a33c66a8f9d616252aa3870926","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.","category":"company","datetime":1784325604,"headline":"Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know"}, {"id":140921076,"url":"https://finnhub.io/api/news?id=e90b6781843d18b10f876394d232d07f21fe86da542e09bf98c448ef73aba319","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","category":"company","datetime":1784206805,"headline":"Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"}, {"id":140899891,"url":"https://finnhub.io/api/news?id=a36ba0e144bfe82ed21483a8912f1a6bcd309292ca81b80b032aae4a07673d42","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.","category":"company","datetime":1784047151,"headline":"Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1"}, {"id":140866963,"url":"https://finnhub.io/api/news?id=130364ae15a54651f7e62443e98dfec75100e6eb8e4e83cc5b6689cb834b073b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.","category":"company","datetime":1783720803,"headline":"Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts"}, {"id":140852250,"url":"https://finnhub.io/api/news?id=ac5e000deec1573246b58ef3e73dbfd5384a5818591638fbfa0eb2e7cd4c5e88","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...","category":"company","datetime":1783609837,"headline":"Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?"}

raw_source {"id":141012190,"url":"https://finnhub.io/api/news?id=51fa8d6c7ae0b7ae5efeba304c16da4ea1ae8d7c25870a47a7c47e0f7c9348a5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.","category":"company","datetime":1784930402,"headline":"Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"}, {"id":141004172,"url":"https://finnhub.io/api/news?id=320990a0a77a181b5302b8633572bf2b889ef0eb3204a5649fbc5f850ba940bc","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.","category":"company","datetime":1784891430,"headline":"Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"}, {"id":141004483,"url":"https://finnhub.io/api/news?id=d316dc643c0ed07feab39f68d8c55616f60cc49d816ac528b488cce1d844c29d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FOSTER CITY, Calif., July 24, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received pri","category":"company","datetime":1784888760,"headline":"CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer"}, {"id":141005066,"url":"https://finnhub.io/api/news?id=9dacf9259e58fd1221029fce5064498f33c276a99b93ce347dbff82166b669fa","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Legend Biotech Corporation stock: strong Carvykti demand lifts Q2 sales; LB2501 CAR-T shows Phase 1 promise. Click for this LEGN update.","category":"company","datetime":1784886309,"headline":"Legend Biotech: Why I'm Ready To Go Long Again"}, {"id":141005749,"url":"https://finnhub.io/api/news?id=f6c84623ba739cad1d4d1b8704f50b464fbf5f72330ced30f12f75dfcb3925f3","image":"","source":"Benzinga","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing","category":"company","datetime":1784874580,"headline":"Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer"}, {"id":141005737,"url":"https://finnhub.io/api/news?id=09b0ee23712127e790437bd7239e1db83cc0d6bbe776a957098f94fa4e6d192b","image":"https://cdn.benzinga.com/files/images/story/2026/07/24/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.","category":"company","datetime":1784874313,"headline":"Two Years to Build or Pay 200% — Which US Pharma Stocks Win?"}, {"id":140997673,"url":"https://finnhub.io/api/news?id=7a6fa4d18085915d1aefb6e1292cc3e2c640721019e1a6c9e4e430ea77ab42de","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.","category":"company","datetime":1784830560,"headline":"Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?"}, {"id":140983154,"url":"https://finnhub.io/api/news?id=b16daf8e0becbbc7259f8a0be20ef81eb811ce33480379e061ca6c61d8f88ee4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.","category":"company","datetime":1784712780,"headline":"Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study"}, {"id":140979262,"url":"https://finnhub.io/api/news?id=9203bb8e2107fe13e333d0412f970c8c33cf9b4acec8cf74ecec2b8c1c045ac4","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...","category":"company","datetime":1784694517,"headline":"Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026"}, {"id":140976444,"url":"https://finnhub.io/api/news?id=08528cb1caaaf45078de4d5021e7b14c87084d9093121bcd4bf95e728b22552c","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FOSTER CITY, Calif., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2026 financial results and provide a business update.","category":"company","datetime":1784664300,"headline":"Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026"}, {"id":140971706,"url":"https://finnhub.io/api/news?id=13cc992af485499b02b200533bbc14748b649883b9c0d88c8b649afb71f397c2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.","category":"company","datetime":1784643746,"headline":"3 Market-Beating Stocks with Solid Fundamentals"}, {"id":140971707,"url":"https://finnhub.io/api/news?id=6c35cb91e508b4f8ad0dc27e911b0bcb4bcd003e8f3b449bbbc4500630a776ab","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FOSTER CITY, Calif., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. The data to be presented, together with Gilead-led symposia and community forums, re","category":"company","datetime":1784642400,"headline":"Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure"}, {"id":140971643,"url":"https://finnhub.io/api/news?id=35926ea2e6b8209804ca6150c6bb35392cd2a13abf2f25b416b8779787e1d1b5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FOSTER CITY, Calif. & RAHWAY, N.J., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacapavi","category":"company","datetime":1784642400,"headline":"Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy"}, {"id":140984273,"url":"https://finnhub.io/api/news?id=23b2809dfaa40777c00116ff9f6b0792a5a0e6e55c1fa12bc61b4c605e91a1dc","image":"https://cdn.benzinga.com/files/images/story/2026/07/21/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.","category":"company","datetime":1784640481,"headline":"Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill"}, {"id":140974991,"url":"https://finnhub.io/api/news?id=854bfc7ad85bff420aaeb28a7ae28bdcff9fbffa47d7637a5a5081fb666f4bf5","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences will release its second-quarter earnings soon, and analysts anticipate a triple-digit profit dip.","category":"company","datetime":1784638566,"headline":"Gilead Sciences' Quarterly Earnings Preview: What You Need to Know"}, {"id":140984274,"url":"https://finnhub.io/api/news?id=1e1f5e47f53409ca122f2682f8010a0a80abd6d64584fc97a69c6f6f60ee23f5","image":"","source":"Benzinga","related":"GILD","summary":"Leerink Partners analyst Daina Graybosch downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.","category":"company","datetime":1784637754,"headline":"Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127"}, {"id":140969430,"url":"https://finnhub.io/api/news?id=a7decbabf581acda978185fe2485a53ac39fd75873742782db0837e286b75924","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.","category":"company","datetime":1784634104,"headline":"Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More"}, {"id":140965762,"url":"https://finnhub.io/api/news?id=6eb8b785ba528c1bad779d5d5999eb122a468b8980d539a3966a38c562564001","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market capitalization of","category":"company","datetime":1784574049,"headline":"Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"}, {"id":140939218,"url":"https://finnhub.io/api/news?id=0e03b539cb341075b72f4a43979aac043c7a90a33c66a8f9d616252aa3870926","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.","category":"company","datetime":1784325604,"headline":"Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know"}, {"id":140934498,"url":"https://finnhub.io/api/news?id=d5e325853357032801312770e7b99a6265e4d99d76ac402f46ae2fcc455526af","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?","category":"company","datetime":1784307294,"headline":"Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move."}, {"id":140922748,"url":"https://finnhub.io/api/news?id=c0dfa85a65bb4922972f455c823eb8dfd1026d0cf6586ebf544156f0c2ac810d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...","category":"company","datetime":1784221200,"headline":"Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions"}, {"id":140932087,"url":"https://finnhub.io/api/news?id=af7f0df37352e62c6b28f0323218c8c2f132887dfdfa682cfca6c2a02a0443c0","image":"https://cdn.benzinga.com/files/images/story/2026/07/16/Kalshi-Hosts-Free-Groceries.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.","category":"company","datetime":1784208592,"headline":"Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings"}, {"id":140921076,"url":"https://finnhub.io/api/news?id=e90b6781843d18b10f876394d232d07f21fe86da542e09bf98c448ef73aba319","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","category":"company","datetime":1784206805,"headline":"Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"}, {"id":140919690,"url":"https://finnhub.io/api/news?id=872dcdb1b794074e3c3b47d33c5b3c438dabc0540094151f4bc85d87bd2f0ffe","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus","category":"company","datetime":1784203200,"headline":"Kalshi Will Offer Sports-Style Betting on Drug Trial Results"}, {"id":140908120,"url":"https://finnhub.io/api/news?id=b8c6e3ec8611b248e30d1d53e25eef6984f5dfa5a8b1b6aed9bb11253f63d462","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.","category":"company","datetime":1784121009,"headline":"Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?"}, {"id":140899891,"url":"https://finnhub.io/api/news?id=a36ba0e144bfe82ed21483a8912f1a6bcd309292ca81b80b032aae4a07673d42","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.","category":"company","datetime":1784047151,"headline":"Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1"}, {"id":140888428,"url":"https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.","category":"company","datetime":1783964231,"headline":"Own Regeneron For Biotech Growth? Incyte Is Making Its Case."}, {"id":140877198,"url":"https://finnhub.io/api/news?id=e3025ddb2315ad436973d69f7d2db5fb33b836836dd518e233c2710081814e73","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead's expansion beyond HIV therapies will surprise many investors.","category":"company","datetime":1783863780,"headline":"Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong."}, {"id":140866963,"url":"https://finnhub.io/api/news?id=130364ae15a54651f7e62443e98dfec75100e6eb8e4e83cc5b6689cb834b073b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.","category":"company","datetime":1783720803,"headline":"Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts"}, {"id":140865010,"url":"https://finnhub.io/api/news?id=4c3d354a7751b7e3c25635309edaa7acf06881ecc4f247a89a15c996d87b178e","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"GILD","summary":"Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.","category":"company","datetime":1783710301,"headline":"What's going on in today's session: S&P500 movers"}, {"id":140864127,"url":"https://finnhub.io/api/news?id=9227f326155bc65e6ac391b8296334e42172064228b4e320a60cf8fcc20478ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"You don't need to predict a recession to prepare your portfolio. These two stocks can help.","category":"company","datetime":1783700400,"headline":"2 Recession-Resistant Dividend Stocks to Buy and Hold"}, {"id":140852250,"url":"https://finnhub.io/api/news?id=ac5e000deec1573246b58ef3e73dbfd5384a5818591638fbfa0eb2e7cd4c5e88","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...","category":"company","datetime":1783609837,"headline":"Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?"}, {"id":140848787,"url":"https://finnhub.io/api/news?id=eabe957d0c0b9b815d98c056ebb784e9646d30a40a06c374e49af8d7cf98963b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...","category":"company","datetime":1783581131,"headline":"Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access"}, {"id":140848788,"url":"https://finnhub.io/api/news?id=dc3466b85c9d3b577283402c50ba6938b90872fa56016a641bd868b9891d35ce","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...","category":"company","datetime":1783577506,"headline":"Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative"}, {"id":140845528,"url":"https://finnhub.io/api/news?id=2aade6fef19996af1a16773a2508eaa78eb71c372e113ca6361a9b9ecbd820d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Cheap Stocks to Buy Right Now. On June 30, Morgan Stanley kept its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and maintained its price target of $168. The research firm’s positive view is based on a number of factors, including the company’s growth outlook […]","category":"company","datetime":1783543706,"headline":"Morgan Stanley Keeps Buy Rating on Gilead (GILD)"}, {"id":140843362,"url":"https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri","category":"company","datetime":1783529860,"headline":"Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"}, {"id":140841649,"url":"https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th","category":"company","datetime":1783523510,"headline":"Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"}, {"id":140843952,"url":"https://finnhub.io/api/news?id=3018272f12e8143d30f18b292420d5c4acbe0d3d8e83b86b9588d1bebf4876ac","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253448108/image_2253448108.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Legend Biotech Corporation outlook: Carvykti drives upside in multiple myeloma, plus LB2501 optionality. Click for this updated look at LEGN stock.","category":"company","datetime":1783521966,"headline":"A New Look At Legend Biotech: Plenty Of Upside For Carvykti"}, {"id":140851698,"url":"https://finnhub.io/api/news?id=b4e512fa99b6550d6b56cced8ce87e7d88b54232eb7304750cce6e9382f5187a","image":"","source":"Benzinga","related":"GILD","summary":"Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $168 to $166.","category":"company","datetime":1783515400,"headline":"Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166"}, {"id":140833905,"url":"https://finnhub.io/api/news?id=b7c7d72359df18e87aeb7f9f1a9c6e770753c69cfb1ebcd61539db915ac0ba41","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"GILD","summary":"Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.","category":"company","datetime":1783451100,"headline":"Stay informed with the top movers within the S&P500 index on Tuesday."}, {"id":140832952,"url":"https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”","category":"company","datetime":1783441817,"headline":"Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"}, {"id":140831554,"url":"https://finnhub.io/api/news?id=174db13fb0f1e19cbcbf6a1fd9f68d06644903e92d588133dbe8fd7555210271","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. BBG Advanced Therapies labs and offices BBG Advanced Therapies, a subsidiary","category":"company","datetime":1783432800,"headline":"BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients"}, {"id":140830183,"url":"https://finnhub.io/api/news?id=b38fed36189ed238ffbbcab24b6d07a6ef3f61ad4408f21993e1ce81ed550919","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"– Seasoned executive brings extensive leadership experience spanning corporate development, business development and pipeline strategy – – Track record includes helping build and advance leading oncology franchises at Seagen, CytomX, Gilead and Merus – CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the appointment of Roland Gendron as Chief Business Offi","category":"company","datetime":1783429200,"headline":"Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer"}, {"id":140834932,"url":"https://finnhub.io/api/news?id=2246d8846ed07749cb78eab302827122938dcb09b3a7979b3be63be6fdfa28a2","image":"","source":"Benzinga","related":"GILD","summary":"RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and lowers the price target from $122 to $120.","category":"company","datetime":1783424369,"headline":"RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $120"}, {"id":140830563,"url":"https://finnhub.io/api/news?id=db2174c073837831286ca2c07c1b3b00b29ddae31ee4aaebfa28b835704e34e6","image":"","source":"SeekingAlpha","related":"GILD","summary":"","category":"company","datetime":1783420110,"headline":"SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn"}, {"id":140834933,"url":"https://finnhub.io/api/news?id=6b293444e4d54d1e4f0641cbcd3d59c17c57f96329d19d1b81f439968fc0fa77","image":"","source":"Benzinga","related":"GILD","summary":"Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $157 to $156.","category":"company","datetime":1783412585,"headline":"Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156"}, {"id":140823613,"url":"https://finnhub.io/api/news?id=6b219e38084e6475784ec645d74c2fa22bed3720375dabbf7ff1d4559a279cdd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.","category":"company","datetime":1783362960,"headline":"Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?"}, {"id":140822547,"url":"https://finnhub.io/api/news?id=1afd47739aab53e639af99f3c3555fd4cc84a896ce09a6e979e29cf1ad07ba85","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.","category":"company","datetime":1783353653,"headline":"The Cancer Therapy Strategy VERAXA Is Betting the Company On"}, {"id":140824936,"url":"https://finnhub.io/api/news?id=89bd33c0e677d2320cedd19adf8992de1bb1e9b573a15c20c0d361d0e1d5ffa6","image":"https://cdn.benzinga.com/files/images/story/2026/07/06/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.","category":"company","datetime":1783346723,"headline":"Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says"}, {"id":139322844,"url":"https://finnhub.io/api/news?id=105e9daab0c2bd7d8ef2cbabc00e1a53c7203e51239ddad22d4c210fa5708a54","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls","category":"company","datetime":1783345670,"headline":"Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls"}, {"id":140819320,"url":"https://finnhub.io/api/news?id=35f52776660d9ec36474180a714ebba89a58bab560a35354ffec23746c014381","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More","category":"company","datetime":1783338748,"headline":"Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More"}, {"id":140820610,"url":"https://finnhub.io/api/news?id=2ebdc7d64c9389ba65a88d68682367fbddb2d05f928e91828f126fedcc2a0fe2","image":"","source":"Benzinga","related":"GILD","summary":"Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.","category":"company","datetime":1783328301,"headline":"Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target"}, {"id":140820591,"url":"https://finnhub.io/api/news?id=5f750f67d1264ede1d518e7585b75215f8500e34a761806577243eea842751b3","image":"https://cdn.benzinga.com/files/images/story/2026/07/06/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Wall Street analysts upgraded several top stocks, including T-Mobile, US Bancorp, Gilead Sciences, Tenable Holdings, and Murphy USA. See their ratings and price targets.","category":"company","datetime":1783321476,"headline":"This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday"}, {"id":140820612,"url":"https://finnhub.io/api/news?id=eafaf10ccf7ca39c18ff6de9c9a793297104b4ad0e9e3b194066cd675e25fd59","image":"","source":"Benzinga","related":"GILD","summary":"HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.","category":"company","datetime":1783317086,"headline":"HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155"}, {"id":140813326,"url":"https://finnhub.io/api/news?id=a87faf6062bae732bbb61d052b384570d5f68768c6396879fee5d5a93acbf376","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate […]","category":"company","datetime":1783256348,"headline":"Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?"}, {"id":140803221,"url":"https://finnhub.io/api/news?id=f9b984573fef806f0ce62d3cac8b8be11559fd8da1e60f999ea7a06beb7ac99a","image":"https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536","source":"Benzinga","related":"GILD","summary":"Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization of","category":"company","datetime":1783080954,"headline":"If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today"}, {"id":140783749,"url":"https://finnhub.io/api/news?id=e602ea44e0147c83c9aceac989c84a586f3fb3f31f940b5b306ac13117dc1bac","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.","category":"company","datetime":1782925560,"headline":"KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug"}, {"id":140772314,"url":"https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964","image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536","source":"SeekingAlpha","related":"GILD","summary":"Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.","category":"company","datetime":1782810196,"headline":"Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"}, {"id":140761182,"url":"https://finnhub.io/api/news?id=d2e8a348646d5e6af80531e0527622b8d97095e08753e2f288a44d8b87ad6d68","image":"https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp","source":"ChartMill","related":"GILD","summary":"Gilead Sciences offers a sustainable 2.65% dividend yield with strong financial health. This article explains how to find reliable income stocks using ChartMill’s dividend, health, and profitability filters.","category":"company","datetime":1782736826,"headline":"Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector"}, {"id":140761605,"url":"https://finnhub.io/api/news?id=711bbcaa4e6c6f8f4def15798e9b51c879c48983f3b74c54917a4d6ed5a4b9bf","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.","category":"company","datetime":1782735720,"headline":"Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?"}, {"id":140750602,"url":"https://finnhub.io/api/news?id=f27f6b207bda2bcdc279e668a6badafa286297ecc1fd4ccaff83dd1b21071abd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]","category":"company","datetime":1782605263,"headline":"Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC"}, {"id":140743691,"url":"https://finnhub.io/api/news?id=81c088d09dc5369db4e13083323e79094fe09aada06fa0bf6bd53a75e7bf3afd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...","category":"company","datetime":1782533717,"headline":"Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?"}, {"id":140743123,"url":"https://finnhub.io/api/news?id=360b306066ef417a66fd2a08efe95ae65504423853afe06231bee4bb2591395e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...","category":"company","datetime":1782529827,"headline":"Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe"}, {"id":140736560,"url":"https://finnhub.io/api/news?id=4645ec76f483a836c0f6906d636fbc70fe828b7b4f91e2b5ab3ef7a80fb91fb7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.","category":"company","datetime":1782485100,"headline":"Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?"}, {"id":140738484,"url":"https://finnhub.io/api/news?id=ef5060389f60276f62729917f5f1870ad05f242bbb0eaf9b66b4ccc315ed7ca7","image":"","source":"Benzinga","related":"GILD","summary":"https://www.cdc.gov/ebola/situation-summary/index.html","category":"company","datetime":1782479453,"headline":"CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low"}, {"id":140734602,"url":"https://finnhub.io/api/news?id=75a2245510d373a6d6c50defb3e2c0bb9b28a68cf403c213f8026e5b42c2364d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"GILD","summary":"Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]","category":"company","datetime":1782472268,"headline":"Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results"}

data_source finnhub_news_keyword_model

article_count 8

negative_hits 0

positive_hits 2

recomputed_at_score true

sentiment_score_raw 0.6

source_article_count 66

discarded_article_count 47

sentimentPoints 4

Dimension contribution

Dimension Raw Max Norm % Contrib

基本面 4.6 5/110 92% 4.6

資金流 10.8 20/110 54% 10.8

市場環境 6.2 15/110 41.33% 6.2

催化劑 2 20/110 10% 2

風險管理 6.5 10/110 65% 6.5

技術信號 17.5 30/110 58.33% 17.5

情緒分析 4 10/110 40% 4

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 1/50

ret_5d -0.037

max_score 50

max_total 50

raw_total 1

vcp_bonus 0

vol_ratio 0.7394

ret_points 0

vol_points 0

range_ratio 0.6967

volat_points 0

day_range_pct 0.0202

model_version cursor_18_27_news_v2_160

available_bars 30

breakout_points 0

partial_history false

pullback_points 1

breakout_vol_bonus 0

first_breakout_20d false

return_window_days 5

first_breakout_bonus 0

breakout_quality_points 0

Risk management

level Medium

reason risk management score >= 6.5/10

position

score 1.3

details

atrPct 3.0629

turnoverUsdM 715.0326

liquidityPoints 0.6

volatilityPoints 0.7

rrPoints 1.4

stopLevels

symbol US.GILD

rr_range 1:1.0-1:2.5

risk_profile 中等

stop_loss_price 121.3886

strength_details

ma_score 2

atr_score 1

rsi_score 1

macd_score 1.5

volume_score 1

market_adjustment 1

risk_reward_ratio 1

stop_loss_percent 6.1

take_profit_price 135.7755

target_multiplier 1.6

technical_strength 1.33

take_profit_percent 5

positionPoints 1.3

stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used

sector Health Care

concentratedSectorPenalty 0

riskRewardRatio 1.2

stopLossPercent 6.1259

diversificationPoints 2

Calculation audit log

基本面分析總分: 4.6/5分
資金流分析總分: 10.8/20分
市場環境分析總分: 6.2/15分
催化劑分析: 2/20分
風險管理總分: 6.5/10分
技術信號分析總分: 17.5/30分
情緒分析: 4/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx

value 85.71

atr

atr 3.9607

rule ATR / current price; lower volatility scores higher

score 4

atr_pct 3.06

cci

rule Cursor_18.24 CCI bands

level 弱勢

score 4

value -29.32

cmf

rule Cursor_18.24 CMF bands

level 平衡

score 4

value 0.0794

kdj

d 35.85

j 3.41

k 25.04

rule Cursor_18.24 K/D cross

score 0

signal 死叉

mfi

rule Cursor_18.24 MFI bands

level 平衡

score 6

value 54.03

obv

rule Cursor_18.24 recent_slope vs previous_slope

score 10

trend 強流入

value -40569900

recentSlope -671220

previousSlope -1470370

rsi

value 49.51

sar

rule Cursor_18.24 Parabolic SAR

score 4

trend 下降

value 139.6536

position SAR喺價上

distancePct 8

previousTrend 下降

ma50

value 129.653

macd

macd 0.6594

trend 中性偏多

signal 0.9696

histogram -0.3102

vwap

rule Cursor_18.24 VWAP 20D consecutive close

score 2

value 130.7728

position <VWAP

consecutiveAbove 0

volume

rule Cursor_18.24 volume ratio

level 空升

ratio 0.75

score 2

avgVolume 7392030

currentVolume 5529600

derived

ma20 131.0985

ma50 129.653

prevClose 130.86

avgVolume10 5874660

avgVolume20 7392030

changePercent -1.18

avgVolumeForScore 7392030

ma_cross

ma20 131.0985

ma50 129.653

rule Cursor_18.24 MA20/MA50 cross

cross 接近

score 6

prevMa20 130.825

prevMa50 129.7656

spreadPct 1.11

isVolumeBreakout false

bollinger

lower 124.8123

upper 137.3847

position 中間

rsi_short

value 7.12

macd_short

macd 0

trend 中性

signal 0

histogram 0

volume_ratio

ratio 0.75

Raw calculation JSON

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.06294950119867,
        "turnoverUsdM": 715.032576,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.GILD",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 121.3886,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.1,
      "take_profit_price": 135.7755,
      "target_multiplier": 1.6,
      "technical_strength": 1.33,
      "take_profit_percent": 5
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.12589900239734,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 52.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 51.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 131.0985,
    "ma50": 129.653,
    "close": 129.31,
    "prevClose": 130.86,
    "avgVolume20": 7392030,
    "volumeRatio": 0.75,
    "changePercent": -1.18
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.037012213285671725,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.7394426231919621,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.6967396709366686,
      "volat_points": 0,
      "day_range_pct": 0.020184030624081608,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 52.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.6,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 92,
        "contribution": 4.6
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 17.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 58.33,
        "contribution": 17.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 51.6,
    "details": [
      "基本面分析總分: 4.6/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 17.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.6,
      "資金流": 10.8,
      "市場環境": 6.2,
      "情緒分析": 4,
      "技術信號": 17.5,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.6,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.75,
          "turnoverUsdM": 715.032576,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 2.4,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.GILD",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 1.8,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 18.7
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 711.71300025,
                "ma50": 718.2872022,
                "name": "QQQ",
                "close": 684.22998,
                "points": 0.4
              },
              "spy": {
                "ma20": 746.1530053500001,
                "ma50": 745.0680014400001,
                "name": "SPY",
                "close": 738.92999,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.06294950119867,
          "atrPoints": 2,
          "cciPoints": 1.6,
          "vixPoints": 1.8,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141012190,
                "url": "https://finnhub.io/api/news?id=51fa8d6c7ae0b7ae5efeba304c16da4ea1ae8d7c25870a47a7c47e0f7c9348a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.",
                "category": "company",
                "datetime": 1784930402,
                "headline": "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 141004172,
                "url": "https://finnhub.io/api/news?id=320990a0a77a181b5302b8633572bf2b889ef0eb3204a5649fbc5f850ba940bc",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.",
                "category": "company",
                "datetime": 1784891430,
                "headline": "Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"
              },
              {
                "id": 140979262,
                "url": "https://finnhub.io/api/news?id=9203bb8e2107fe13e333d0412f970c8c33cf9b4acec8cf74ecec2b8c1c045ac4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...",
                "category": "company",
                "datetime": 1784694517,
                "headline": "Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026"
              },
              {
                "id": 140939218,
                "url": "https://finnhub.io/api/news?id=0e03b539cb341075b72f4a43979aac043c7a90a33c66a8f9d616252aa3870926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.",
                "category": "company",
                "datetime": 1784325604,
                "headline": "Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140921076,
                "url": "https://finnhub.io/api/news?id=e90b6781843d18b10f876394d232d07f21fe86da542e09bf98c448ef73aba319",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784206805,
                "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140899891,
                "url": "https://finnhub.io/api/news?id=a36ba0e144bfe82ed21483a8912f1a6bcd309292ca81b80b032aae4a07673d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.",
                "category": "company",
                "datetime": 1784047151,
                "headline": "Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1"
              },
              {
                "id": 140866963,
                "url": "https://finnhub.io/api/news?id=130364ae15a54651f7e62443e98dfec75100e6eb8e4e83cc5b6689cb834b073b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783720803,
                "headline": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140852250,
                "url": "https://finnhub.io/api/news?id=ac5e000deec1573246b58ef3e73dbfd5384a5818591638fbfa0eb2e7cd4c5e88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...",
                "category": "company",
                "datetime": 1783609837,
                "headline": "Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?"
              }
            ],
            "raw_source": [
              {
                "id": 141012190,
                "url": "https://finnhub.io/api/news?id=51fa8d6c7ae0b7ae5efeba304c16da4ea1ae8d7c25870a47a7c47e0f7c9348a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.",
                "category": "company",
                "datetime": 1784930402,
                "headline": "Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know"
              },
              {
                "id": 141004172,
                "url": "https://finnhub.io/api/news?id=320990a0a77a181b5302b8633572bf2b889ef0eb3204a5649fbc5f850ba940bc",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) offers a 2.52% dividend yield backed by strong fundamentals. With a Dividend Rating of 7/10, Profitability of 9/10, and Health of 8/10, it's a high-quality sustainable income stock.",
                "category": "company",
                "datetime": 1784891430,
                "headline": "Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors"
              },
              {
                "id": 141004483,
                "url": "https://finnhub.io/api/news?id=d316dc643c0ed07feab39f68d8c55616f60cc49d816ac528b488cce1d844c29d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., July 24, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received pri",
                "category": "company",
                "datetime": 1784888760,
                "headline": "CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer"
              },
              {
                "id": 141005066,
                "url": "https://finnhub.io/api/news?id=9dacf9259e58fd1221029fce5064498f33c276a99b93ce347dbff82166b669fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Legend Biotech Corporation stock: strong Carvykti demand lifts Q2 sales; LB2501 CAR-T shows Phase 1 promise. Click for this LEGN update.",
                "category": "company",
                "datetime": 1784886309,
                "headline": "Legend Biotech: Why I'm Ready To Go Long Again"
              },
              {
                "id": 141005749,
                "url": "https://finnhub.io/api/news?id=f6c84623ba739cad1d4d1b8704f50b464fbf5f72330ced30f12f75dfcb3925f3",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing",
                "category": "company",
                "datetime": 1784874580,
                "headline": "Gilead Receives EMA CHMP Recommendation For Authorization For Trodelvy Plus Keytruda To Treat Metastatic Triple-Negative Breast Cancer"
              },
              {
                "id": 141005737,
                "url": "https://finnhub.io/api/news?id=09b0ee23712127e790437bd7239e1db83cc0d6bbe776a957098f94fa4e6d192b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/24/Closse-up-Shot-Of-White-Pills-On-Conveyo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.",
                "category": "company",
                "datetime": 1784874313,
                "headline": "Two Years to Build or Pay 200% — Which US Pharma Stocks Win?"
              },
              {
                "id": 140997673,
                "url": "https://finnhub.io/api/news?id=7a6fa4d18085915d1aefb6e1292cc3e2c640721019e1a6c9e4e430ea77ab42de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.",
                "category": "company",
                "datetime": 1784830560,
                "headline": "Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?"
              },
              {
                "id": 140983154,
                "url": "https://finnhub.io/api/news?id=b16daf8e0becbbc7259f8a0be20ef81eb811ce33480379e061ca6c61d8f88ee4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.",
                "category": "company",
                "datetime": 1784712780,
                "headline": "Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study"
              },
              {
                "id": 140979262,
                "url": "https://finnhub.io/api/news?id=9203bb8e2107fe13e333d0412f970c8c33cf9b4acec8cf74ecec2b8c1c045ac4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...",
                "category": "company",
                "datetime": 1784694517,
                "headline": "Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026"
              },
              {
                "id": 140976444,
                "url": "https://finnhub.io/api/news?id=08528cb1caaaf45078de4d5021e7b14c87084d9093121bcd4bf95e728b22552c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2026 financial results and provide a business update.",
                "category": "company",
                "datetime": 1784664300,
                "headline": "Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026"
              },
              {
                "id": 140971706,
                "url": "https://finnhub.io/api/news?id=13cc992af485499b02b200533bbc14748b649883b9c0d88c8b649afb71f397c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
                "category": "company",
                "datetime": 1784643746,
                "headline": "3 Market-Beating Stocks with Solid Fundamentals"
              },
              {
                "id": 140971707,
                "url": "https://finnhub.io/api/news?id=6c35cb91e508b4f8ad0dc27e911b0bcb4bcd003e8f3b449bbbc4500630a776ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. The data to be presented, together with Gilead-led symposia and community forums, re",
                "category": "company",
                "datetime": 1784642400,
                "headline": "Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure"
              },
              {
                "id": 140971643,
                "url": "https://finnhub.io/api/news?id=35926ea2e6b8209804ca6150c6bb35392cd2a13abf2f25b416b8779787e1d1b5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FOSTER CITY, Calif. & RAHWAY, N.J., July 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacapavi",
                "category": "company",
                "datetime": 1784642400,
                "headline": "Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy"
              },
              {
                "id": 140984273,
                "url": "https://finnhub.io/api/news?id=23b2809dfaa40777c00116ff9f6b0792a5a0e6e55c1fa12bc61b4c605e91a1dc",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead &amp; Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.",
                "category": "company",
                "datetime": 1784640481,
                "headline": "Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill"
              },
              {
                "id": 140974991,
                "url": "https://finnhub.io/api/news?id=854bfc7ad85bff420aaeb28a7ae28bdcff9fbffa47d7637a5a5081fb666f4bf5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences will release its second-quarter earnings soon, and analysts anticipate a triple-digit profit dip.",
                "category": "company",
                "datetime": 1784638566,
                "headline": "Gilead Sciences' Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 140984274,
                "url": "https://finnhub.io/api/news?id=1e1f5e47f53409ca122f2682f8010a0a80abd6d64584fc97a69c6f6f60ee23f5",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Leerink Partners  analyst Daina Graybosch   downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.",
                "category": "company",
                "datetime": 1784637754,
                "headline": "Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127"
              },
              {
                "id": 140969430,
                "url": "https://finnhub.io/api/news?id=a7decbabf581acda978185fe2485a53ac39fd75873742782db0837e286b75924",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.",
                "category": "company",
                "datetime": 1784634104,
                "headline": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More"
              },
              {
                "id": 140965762,
                "url": "https://finnhub.io/api/news?id=6eb8b785ba528c1bad779d5d5999eb122a468b8980d539a3966a38c562564001",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1784574049,
                "headline": "Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today"
              },
              {
                "id": 140939218,
                "url": "https://finnhub.io/api/news?id=0e03b539cb341075b72f4a43979aac043c7a90a33c66a8f9d616252aa3870926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.",
                "category": "company",
                "datetime": 1784325604,
                "headline": "Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140934498,
                "url": "https://finnhub.io/api/news?id=d5e325853357032801312770e7b99a6265e4d99d76ac402f46ae2fcc455526af",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?",
                "category": "company",
                "datetime": 1784307294,
                "headline": "Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move."
              },
              {
                "id": 140922748,
                "url": "https://finnhub.io/api/news?id=c0dfa85a65bb4922972f455c823eb8dfd1026d0cf6586ebf544156f0c2ac810d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...",
                "category": "company",
                "datetime": 1784221200,
                "headline": "Kalshi Allows Betting On Clinical Trials And FDA Drug Decisions"
              },
              {
                "id": 140932087,
                "url": "https://finnhub.io/api/news?id=af7f0df37352e62c6b28f0323218c8c2f132887dfdfa682cfca6c2a02a0443c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/16/Kalshi-Hosts-Free-Groceries.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.",
                "category": "company",
                "datetime": 1784208592,
                "headline": "Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings"
              },
              {
                "id": 140921076,
                "url": "https://finnhub.io/api/news?id=e90b6781843d18b10f876394d232d07f21fe86da542e09bf98c448ef73aba319",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1784206805,
                "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140919690,
                "url": "https://finnhub.io/api/news?id=872dcdb1b794074e3c3b47d33c5b3c438dabc0540094151f4bc85d87bd2f0ffe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Kalshi Will Offer Sports-Style Betting on Drug Trial Results"
              },
              {
                "id": 140908120,
                "url": "https://finnhub.io/api/news?id=b8c6e3ec8611b248e30d1d53e25eef6984f5dfa5a8b1b6aed9bb11253f63d462",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.",
                "category": "company",
                "datetime": 1784121009,
                "headline": "Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?"
              },
              {
                "id": 140899891,
                "url": "https://finnhub.io/api/news?id=a36ba0e144bfe82ed21483a8912f1a6bcd309292ca81b80b032aae4a07673d42",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.",
                "category": "company",
                "datetime": 1784047151,
                "headline": "Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1"
              },
              {
                "id": 140888428,
                "url": "https://finnhub.io/api/news?id=ed15eb87356bea39d17c294679a13f32dbb5cc7c416f7aa1579ca7722654403b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.",
                "category": "company",
                "datetime": 1783964231,
                "headline": "Own Regeneron For Biotech Growth? Incyte Is Making Its Case."
              },
              {
                "id": 140877198,
                "url": "https://finnhub.io/api/news?id=e3025ddb2315ad436973d69f7d2db5fb33b836836dd518e233c2710081814e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead's expansion beyond HIV therapies will surprise many investors.",
                "category": "company",
                "datetime": 1783863780,
                "headline": "Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong."
              },
              {
                "id": 140866963,
                "url": "https://finnhub.io/api/news?id=130364ae15a54651f7e62443e98dfec75100e6eb8e4e83cc5b6689cb834b073b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.",
                "category": "company",
                "datetime": 1783720803,
                "headline": "Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts"
              },
              {
                "id": 140865010,
                "url": "https://finnhub.io/api/news?id=4c3d354a7751b7e3c25635309edaa7acf06881ecc4f247a89a15c996d87b178e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1783710301,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 140864127,
                "url": "https://finnhub.io/api/news?id=9227f326155bc65e6ac391b8296334e42172064228b4e320a60cf8fcc20478ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "You don't need to predict a recession to prepare your portfolio. These two stocks can help.",
                "category": "company",
                "datetime": 1783700400,
                "headline": "2 Recession-Resistant Dividend Stocks to Buy and Hold"
              },
              {
                "id": 140852250,
                "url": "https://finnhub.io/api/news?id=ac5e000deec1573246b58ef3e73dbfd5384a5818591638fbfa0eb2e7cd4c5e88",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...",
                "category": "company",
                "datetime": 1783609837,
                "headline": "Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?"
              },
              {
                "id": 140848787,
                "url": "https://finnhub.io/api/news?id=eabe957d0c0b9b815d98c056ebb784e9646d30a40a06c374e49af8d7cf98963b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...",
                "category": "company",
                "datetime": 1783581131,
                "headline": "Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access"
              },
              {
                "id": 140848788,
                "url": "https://finnhub.io/api/news?id=dc3466b85c9d3b577283402c50ba6938b90872fa56016a641bd868b9891d35ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...",
                "category": "company",
                "datetime": 1783577506,
                "headline": "Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative"
              },
              {
                "id": 140845528,
                "url": "https://finnhub.io/api/news?id=2aade6fef19996af1a16773a2508eaa78eb71c372e113ca6361a9b9ecbd820d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Cheap Stocks to Buy Right Now. On June 30, Morgan Stanley kept its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and maintained its price target of $168. The research firm’s positive view is based on a number of factors, including the company’s growth outlook […]",
                "category": "company",
                "datetime": 1783543706,
                "headline": "Morgan Stanley Keeps Buy Rating on Gilead (GILD)"
              },
              {
                "id": 140843362,
                "url": "https://finnhub.io/api/news?id=597f4902dfd05c08eeacaf56c3d2203bd898010321778f32442a1e1312d5a219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri",
                "category": "company",
                "datetime": 1783529860,
                "headline": "Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140843952,
                "url": "https://finnhub.io/api/news?id=3018272f12e8143d30f18b292420d5c4acbe0d3d8e83b86b9588d1bebf4876ac",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253448108/image_2253448108.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Legend Biotech Corporation outlook: Carvykti drives upside in multiple myeloma, plus LB2501 optionality. Click for this updated look at LEGN stock.",
                "category": "company",
                "datetime": 1783521966,
                "headline": "A New Look At Legend Biotech: Plenty Of Upside For Carvykti"
              },
              {
                "id": 140851698,
                "url": "https://finnhub.io/api/news?id=b4e512fa99b6550d6b56cced8ce87e7d88b54232eb7304750cce6e9382f5187a",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $168 to $166.",
                "category": "company",
                "datetime": 1783515400,
                "headline": "Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $166"
              },
              {
                "id": 140833905,
                "url": "https://finnhub.io/api/news?id=b7c7d72359df18e87aeb7f9f1a9c6e770753c69cfb1ebcd61539db915ac0ba41",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1783451100,
                "headline": "Stay informed with the top movers within the S&P500 index on Tuesday."
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140831554,
                "url": "https://finnhub.io/api/news?id=174db13fb0f1e19cbcbf6a1fd9f68d06644903e92d588133dbe8fd7555210271",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "BBG Advanced Therapies, a subsidiary of San Antonio-based nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas—marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells. BBG Advanced Therapies labs and offices BBG Advanced Therapies, a subsidiary",
                "category": "company",
                "datetime": 1783432800,
                "headline": "BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients"
              },
              {
                "id": 140830183,
                "url": "https://finnhub.io/api/news?id=b38fed36189ed238ffbbcab24b6d07a6ef3f61ad4408f21993e1ce81ed550919",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "– Seasoned executive brings extensive leadership experience spanning corporate development, business development and pipeline strategy – – Track record includes helping build and advance leading oncology franchises at Seagen, CytomX, Gilead and Merus – CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the appointment of Roland Gendron as Chief Business Offi",
                "category": "company",
                "datetime": 1783429200,
                "headline": "Stipple Bio Appoints Biopharma Business Development Leader Roland Gendron as Chief Business Officer"
              },
              {
                "id": 140834932,
                "url": "https://finnhub.io/api/news?id=2246d8846ed07749cb78eab302827122938dcb09b3a7979b3be63be6fdfa28a2",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and lowers the price target from $122 to $120.",
                "category": "company",
                "datetime": 1783424369,
                "headline": "RBC Capital Maintains Sector Perform on Gilead Sciences, Lowers Price Target to $120"
              },
              {
                "id": 140830563,
                "url": "https://finnhub.io/api/news?id=db2174c073837831286ca2c07c1b3b00b29ddae31ee4aaebfa28b835704e34e6",
                "image": "",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "",
                "category": "company",
                "datetime": 1783420110,
                "headline": "SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn"
              },
              {
                "id": 140834933,
                "url": "https://finnhub.io/api/news?id=6b293444e4d54d1e4f0641cbcd3d59c17c57f96329d19d1b81f439968fc0fa77",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Truist Securities  analyst Gregory Renza   maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $157 to $156.",
                "category": "company",
                "datetime": 1783412585,
                "headline": "Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156"
              },
              {
                "id": 140823613,
                "url": "https://finnhub.io/api/news?id=6b219e38084e6475784ec645d74c2fa22bed3720375dabbf7ff1d4559a279cdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.",
                "category": "company",
                "datetime": 1783362960,
                "headline": "Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?"
              },
              {
                "id": 140822547,
                "url": "https://finnhub.io/api/news?id=1afd47739aab53e639af99f3c3555fd4cc84a896ce09a6e979e29cf1ad07ba85",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1783353653,
                "headline": "The Cancer Therapy Strategy VERAXA Is Betting the Company On"
              },
              {
                "id": 140824936,
                "url": "https://finnhub.io/api/news?id=89bd33c0e677d2320cedd19adf8992de1bb1e9b573a15c20c0d361d0e1d5ffa6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Feb-19--2020-Foster-City--Ca--Usa.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV &amp; oncology potential.",
                "category": "company",
                "datetime": 1783346723,
                "headline": "Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says"
              },
              {
                "id": 139322844,
                "url": "https://finnhub.io/api/news?id=105e9daab0c2bd7d8ef2cbabc00e1a53c7203e51239ddad22d4c210fa5708a54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1783345670,
                "headline": "Marvell upgraded, Trade Desk downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 140819320,
                "url": "https://finnhub.io/api/news?id=35f52776660d9ec36474180a714ebba89a58bab560a35354ffec23746c014381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More",
                "category": "company",
                "datetime": 1783338748,
                "headline": "Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More"
              },
              {
                "id": 140820610,
                "url": "https://finnhub.io/api/news?id=2ebdc7d64c9389ba65a88d68682367fbddb2d05f928e91828f126fedcc2a0fe2",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.",
                "category": "company",
                "datetime": 1783328301,
                "headline": "Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target"
              },
              {
                "id": 140820591,
                "url": "https://finnhub.io/api/news?id=5f750f67d1264ede1d518e7585b75215f8500e34a761806577243eea842751b3",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/06/Close-Up-Of-Gilead-Sciences-Logo-And-Sig.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Wall Street analysts upgraded several top stocks, including T-Mobile, US Bancorp, Gilead Sciences, Tenable Holdings, and Murphy USA. See their ratings and price targets.",
                "category": "company",
                "datetime": 1783321476,
                "headline": "This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday"
              },
              {
                "id": 140820612,
                "url": "https://finnhub.io/api/news?id=eafaf10ccf7ca39c18ff6de9c9a793297104b4ad0e9e3b194066cd675e25fd59",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "HSBC  analyst Morten Herholdt   upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.",
                "category": "company",
                "datetime": 1783317086,
                "headline": "HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155"
              },
              {
                "id": 140813326,
                "url": "https://finnhub.io/api/news?id=a87faf6062bae732bbb61d052b384570d5f68768c6396879fee5d5a93acbf376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 25, Gilead Sciences announced FDA approval for Trodelvy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). It is now approved as a single agent or in combination with Keytruda, becoming the first antibody-drug conjugate […]",
                "category": "company",
                "datetime": 1783256348,
                "headline": "Is Gilead (GILD) One of the Most Undervalued NASDAQ Stocks to Buy Right Now?"
              },
              {
                "id": 140803221,
                "url": "https://finnhub.io/api/news?id=f9b984573fef806f0ce62d3cac8b8be11559fd8da1e60f999ea7a06beb7ac99a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization of",
                "category": "company",
                "datetime": 1783080954,
                "headline": "If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 140783749,
                "url": "https://finnhub.io/api/news?id=e602ea44e0147c83c9aceac989c84a586f3fb3f31f940b5b306ac13117dc1bac",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.",
                "category": "company",
                "datetime": 1782925560,
                "headline": "KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug"
              },
              {
                "id": 140772314,
                "url": "https://finnhub.io/api/news?id=e10497ea38e4fbad71eb7072d597a29bb43582fc3c78ed5ce80d21a5cf7c2964",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "GILD",
                "summary": "Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.",
                "category": "company",
                "datetime": 1782810196,
                "headline": "Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech"
              },
              {
                "id": 140761182,
                "url": "https://finnhub.io/api/news?id=d2e8a348646d5e6af80531e0527622b8d97095e08753e2f288a44d8b87ad6d68",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "GILD",
                "summary": "Gilead Sciences offers a sustainable 2.65% dividend yield with strong financial health. This article explains how to find reliable income stocks using ChartMill’s dividend, health, and profitability filters.",
                "category": "company",
                "datetime": 1782736826,
                "headline": "Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector"
              },
              {
                "id": 140761605,
                "url": "https://finnhub.io/api/news?id=711bbcaa4e6c6f8f4def15798e9b51c879c48983f3b74c54917a4d6ed5a4b9bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1782735720,
                "headline": "Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?"
              },
              {
                "id": 140750602,
                "url": "https://finnhub.io/api/news?id=f27f6b207bda2bcdc279e668a6badafa286297ecc1fd4ccaff83dd1b21071abd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]",
                "category": "company",
                "datetime": 1782605263,
                "headline": "Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC"
              },
              {
                "id": 140743691,
                "url": "https://finnhub.io/api/news?id=81c088d09dc5369db4e13083323e79094fe09aada06fa0bf6bd53a75e7bf3afd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...",
                "category": "company",
                "datetime": 1782533717,
                "headline": "Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?"
              },
              {
                "id": 140743123,
                "url": "https://finnhub.io/api/news?id=360b306066ef417a66fd2a08efe95ae65504423853afe06231bee4bb2591395e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...",
                "category": "company",
                "datetime": 1782529827,
                "headline": "Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe"
              },
              {
                "id": 140736560,
                "url": "https://finnhub.io/api/news?id=4645ec76f483a836c0f6906d636fbc70fe828b7b4f91e2b5ab3ef7a80fb91fb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.",
                "category": "company",
                "datetime": 1782485100,
                "headline": "Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?"
              },
              {
                "id": 140738484,
                "url": "https://finnhub.io/api/news?id=ef5060389f60276f62729917f5f1870ad05f242bbb0eaf9b66b4ccc315ed7ca7",
                "image": "",
                "source": "Benzinga",
                "related": "GILD",
                "summary": "https://www.cdc.gov/ebola/situation-summary/index.html",
                "category": "company",
                "datetime": 1782479453,
                "headline": "CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low"
              },
              {
                "id": 140734602,
                "url": "https://finnhub.io/api/news?id=75a2245510d373a6d6c50defb3e2c0bb9b28a68cf403c213f8026e5b42c2364d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "GILD",
                "summary": "Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]",
                "category": "company",
                "datetime": 1782472268,
                "headline": "Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 66,
            "discarded_article_count": 47
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 17.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1.8,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.8,
            "vcp_reason": "波幅收縮(14.9%→10.1%)；跌縮量(近10日3日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 7856793.333333333,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 5915300,
              "avg_vol_20": 7478065,
              "avg_vol_30": 7856793.333333333,
              "range_pct_10": 0.10053360142293724,
              "range_pct_20": 0.1310030160080428,
              "range_pct_30": 0.14863506302683482,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7528898558275259,
              "dist_to_20d_high": 0.08036412772918007,
              "down_shrink_days": 3,
              "breakout_level_20d": 140.61,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6763787721123833
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.06294950119867,
              "turnoverUsdM": 715.032576,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.GILD",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 121.3886,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.1,
            "take_profit_price": 135.7755,
            "target_multiplier": 1.6,
            "technical_strength": 1.33,
            "take_profit_percent": 5
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.12589900239734,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 3.9607,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.06
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "弱勢",
      "score": 4,
      "value": -29.32
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0794
    },
    "kdj": {
      "d": 35.85,
      "j": 3.41,
      "k": 25.04,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 54.03
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -40569900,
      "recentSlope": -671220,
      "previousSlope": -1470370
    },
    "rsi": 49.51,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 139.6536,
      "position": "SAR喺價上",
      "distancePct": 8,
      "previousTrend": "下降"
    },
    "ma50": 129.653,
    "macd": {
      "macd": 0.6593791073434829,
      "trend": "中性偏多",
      "signal": 0.9696158109587039,
      "histogram": -0.31023670361522093
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 130.7728,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.75,
      "score": 2,
      "avgVolume": 7392030,
      "currentVolume": 5529600
    },
    "derived": {
      "ma20": 131.0985,
      "ma50": 129.653,
      "prevClose": 130.86,
      "avgVolume10": 5874660,
      "avgVolume20": 7392030,
      "changePercent": -1.18,
      "avgVolumeForScore": 7392030
    },
    "ma_cross": {
      "ma20": 131.0985,
      "ma50": 129.653,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 130.825,
      "prevMa50": 129.7656,
      "spreadPct": 1.11,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 124.8123,
      "upper": 137.3847,
      "position": "中間"
    },
    "rsi_short": 7.12,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.75
    }
  }
}

Raw metrics JSON

{
  "close": 129.31,
  "volume": 5529600,
  "changePercent": -1.18
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.

US.GILD · Gilead Sciences

避免

Score and price trend

Summary

Rolling setup rating

Has the score quality changed?

Signals

Full calculation detail

Market inputs

Metrics snapshot

110-point main rating

基本面 — 4.6/5 · 優秀

Sub-items

資金流 — 10.8/20 · 較差

Sub-items

institutional

details

warning

市場環境 — 6.2/15 · 較差

Sub-items

vix

details

trend

details

qqq

spy

催化劑 — 2/20 · 較差

Sub-items

catalyst

details

風險管理 — 6.5/10 · 一般

Sub-items

position

details

stopLevels

strength_details

diversification

details

技術信號 — 17.5/30 · 較差

Sub-items

vcpPayload

vcp_metrics

情緒分析 — 4/10 · 較差

Sub-items

sentiment

details

sentimentData

Dimension contribution

5D momentum v2 breakdown

Risk management

position

details

stopLevels

strength_details

diversification

details

Calculation audit log

Technical indicators

Raw calculation JSON

Raw metrics JSON